WHO's latest World Malaria Report finds 282 million cases and about 610,000 deaths in 2024, with new tools averting an estimated 170 million cases and 1 million deaths but drug resistance and underfunding threatening progress.([who.int](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025?utm_source=openai)) This forecast explores whether the world can move from fragile gains to sustained declines or even regional elimination over the next 1 to 50 years.
Verdict: The evidence shows that malaria control has saved millions of lives since 2000, yet cases and deaths ticked up again in 2024 and are concentrated in a handful of African countries.([who.int](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025?utm_source=openai)) New vaccines, dual ingredient nets and next generation drugs offer real promise, but resistance, climate shocks and a chronic funding shortfall put elimination targets far out of reach.([who.int](https://www.who.int/news/item/04-12-2025-new-tools-saved-a-million-lives-from-malaria-last-year-but-progress-under-threat-as-drug-resistance-rises?utm_source=openai)) The most likely outcome is a precarious plateau with local breakthroughs rather than rapid global eradication unless financing and innovation both accelerate.
Within a decade, donors and endemic countries close most of the malaria financing gap and deploy vaccines, new drugs and dual ingredient nets at high coverage. Artemisinin resistance stabilises without widespread treatment failure as non artemisinin combinations and triple therapies are introduced. Targeted vector control and urban planning slow the spread of Anopheles stephensi, enabling regional elimination in several African and Asian countries by the 2040s.
Funding remains around current levels in real terms, allowing maintenance of core interventions but not universal scale up. Artemisinin resistance expands slowly across parts of Africa but remains partially manageable with adjusted combinations and surveillance. Global cases and deaths hover around today's levels with gradual declines in some countries offset by setbacks in conflict zones and rapidly growing urban areas.
Drug resistance accelerates, undermining first line artemisinin based therapies across much of sub Saharan Africa within 10 to 15 years. Funding falls further as donor priorities shift and domestic budgets strain, forcing rationing of nets, diagnostics and treatment. Malaria deaths climb substantially, especially among children under five, erasing a large share of the gains since 2000 and triggering humanitarian crises in high burden regions.
A disruptive technology such as highly effective gene drive mosquitoes or an ultra long acting injectable prophylactic proves safe, acceptable and field ready sooner than expected. Some countries achieve rapid drops in transmission even in the face of resistance and climate pressures. However, uneven adoption, ethical debates and cross border ecological concerns create a patchwork of success and backlash.
Developments: Over the next year, countries and partners respond to the 2025 report by adjusting national strategic plans and seeking to restore some funding.([who.int](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025?utm_source=openai)) More African countries will introduce WHO recommended vaccines into routine immunisation and expand seasonal chemoprevention, reaching more children.([who.int](https://www.who.int/news/item/04-12-2025-new-tools-saved-a-million-lives-from-malaria-last-year-but-progress-under-threat-as-drug-resistance-rises?utm_source=openai)) Resistance monitoring networks refine maps of artemisinin partial resistance and pfhrp2 deletions that undermine some rapid tests.
Risks: Short term budget cuts or currency crises in key donor and endemic countries could delay procurement of nets, diagnostics and drugs. Humanitarian emergencies and conflicts in high burden states may disrupt campaigns and treatment access, leading to local spikes in mortality. Misinterpretation of early vaccine impact could cause complacency and underinvestment in other tools.
Outlook: One year from now, overall malaria burden is likely to resemble today's with perhaps slight improvements where vaccines scale up quickly. Data on resistance and intervention performance will be clearer. The balance of risk still favours continued vigilance rather than any relaxation of control efforts.
Developments: Within two years, several countries are likely to have integrated vaccines, improved nets and expanded chemoprevention into routine services at scale, especially in parts of Africa.([who.int](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025?utm_source=openai)) Early adopting countries may begin to show measurable declines in severe disease among young children. Global product pipelines for non artemisinin combination therapies and next generation diagnostics advance toward regulatory decisions.
Risks: If funding does not grow, scaling new tools could cannibalise budgets for case management and surveillance, weakening the overall response. Emerging resistance to partner drugs used with artemisinin or in new combinations may appear sooner than expected. Climate anomalies, including flooding and heatwaves, could expand transmission seasons in vulnerable regions, offsetting gains from interventions.
Outlook: Two years from now, the world will see clearer proof that combined tool packages can cut malaria in some settings. However, global totals will likely show only modest shifts due to lags in scale up and countervailing pressures. The strategic question will be whether to double down on integrated packages or spread limited resources thinly.
Developments: By year three, first wave vaccine countries may register substantial reductions in severe paediatric malaria and hospitalisations if coverage and supply chains hold. Some regions could pilot deployment of new oral therapies such as ganaplacide-lumefantrine, especially where artemisinin resistance is strongest.([who.int](https://www.who.int/news/item/04-12-2025-new-tools-saved-a-million-lives-from-malaria-last-year-but-progress-under-threat-as-drug-resistance-rises?utm_source=openai)) Urban malaria strategies targeting Anopheles stephensi, including environmental management and targeted spraying, mature in a few megacities.
Risks: Delayed or inequitable access to new drugs may leave high burden countries exposed while lower burden or wealthier markets benefit first. Safety signals or operational challenges with vaccines or new therapies could slow uptake or trigger public distrust. Urban growth outpacing planning may create new breeding sites that undermine city level interventions.
Outlook: Three years from now, a handful of countries could be on accelerated trajectories toward major burden reduction, validating integrated, data driven approaches. Yet many high burden settings will still struggle with fragile systems and funding gaps. Global averages could mask widening divergence between leaders and laggards.
Developments: In five years, wider adoption of vaccines, improved nets and new therapies may finally bend global incidence and mortality curves downward again if financing holds.([who.int](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025?utm_source=openai)) Several additional countries might achieve or approach WHO malaria free certification, building on the recent additions of Egypt, Cabo Verde, Georgia, Suriname and Timor Leste.([who.int](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2025?utm_source=openai)) Genomic surveillance and real time data platforms help programme managers adjust interventions more quickly to local conditions.
Risks: If antimalarial resistance spreads more rapidly or combines with high levels of insecticide resistance, traditional tools could lose effectiveness even where coverage is high. Funding fatigue in a context of competing global crises may stall or reverse scale up just as expensive new tools come online. Political instability in even a few high burden countries could drive disproportionate increases in global deaths.
Outlook: Five years from now, the baseline expectation is modest global improvement with standout regional successes. The risk remains that biological and financial headwinds convert a fragile recovery into renewed stagnation. Strategic choices about sustaining investment and accelerating innovation will be decisive in this window.
Developments: Over a decade, countries that combine strong primary health systems with full toolboxes of vaccines, drugs and vector control can push malaria to very low levels or eliminate it nationally. Increased urbanisation, if well planned, may reduce rural transmission in some areas while concentrating risk in informal settlements where targeted action is possible. New long acting prophylactics and next generation diagnostics could simplify prevention and case finding.
Risks: Climate change may shift malaria to new altitudes and latitudes, bringing transmission to previously low risk populations with little immunity. Sustained political commitment is uncertain, and success in some countries may breed complacency and budget cuts elsewhere. A major failure in managing resistance, or emergence of a highly fit multi drug resistant strain, could trigger a global resurgence reminiscent of the chloroquine era.
Outlook: Ten years from now, malaria could be largely controlled in many middle income and a few low income countries, but the disease will likely remain entrenched in some high burden African regions. Global health narratives may celebrate progress while warning of persistent hotspots. Whether the world is on a true elimination trajectory will depend on how seriously resistance and climate risks have been tackled.
Developments: In twenty years, sustained investment, strong health systems and continued innovation could bring regional elimination across large parts of Asia Pacific and Latin America, with substantial reductions in Africa. Integrated vector management, environmental change and economic development may reduce transmission in some former hotspots. A diversified portfolio of drugs, biologics and vaccines would ideally keep ahead of resistance.
Risks: Long run funding fatigue, especially if malaria is perceived as a solved problem in many countries, could leave remaining hotspots chronically under served. Population growth in high burden regions might outpace gains from technology and systems, maintaining substantial absolute case numbers. Unanticipated ecological or evolutionary shifts in mosquito vectors or parasites could create new challenges requiring yet another generation of tools.
Outlook: Twenty years from now, the most realistic outcome is a world where malaria is eliminated in many regions but stubbornly persistent in others. Global burden may be a fraction of today's yet still intolerable for affected communities. The equity gap between malaria free and malaria entrenched areas will be a central ethical issue.
Developments: Across half a century, malaria could plausibly be eliminated as a public health problem in nearly all countries if sustained political will, financing and innovation hold. Historical experience with smallpox and near polio eradication will inform governance, surveillance and financing mechanisms designed to prevent resurgence. Advances in biotechnology, including potentially safe gene drive or other vector control strategies, might have been fully deployed and regulated.
Risks: Deep structural inequalities, governance failures or protracted conflicts could leave a small number of regions as enduring reservoirs of transmission. Climate and ecological disruptions might introduce novel vector species or parasite variants, forcing continual adaptation. Ethical and ecological concerns over powerful genetic technologies may limit or delay their use, requiring longer reliance on traditional tools.
Outlook: Fifty years from now, global malaria elimination is technically conceivable but not guaranteed. The most credible outlook is that humanity greatly reduces the disease's toll yet still faces localised outbreaks and the need for vigilant surveillance. Whether malaria becomes a historical relic or an enduring pocketed scourge will be determined by funding, governance and risk tolerance for new technologies.